Skip to main content
SpringerLink
Log in

Donepezil use in US nursing homes

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background and aims: Donepezil is effective in slowing the progression of Alzheimer’s disease (AD). No data are available on the patterns of donepezil use among nursing home residents. We estimate the prevalence of the use of donepezil and the frequency of its initiation, and describe the demographic and clinical characteristics of residents taking this drug. Methods: We used data from the Minimum Data Set (N=174659). We compared users and non-users of donepezil with respect to demographic, clinical and functional variables. We estimated the 6-month incidence of donepezil use. All analyses were stratified by the admission status of the residents (newly admitted/long-stay). Results: Among those meeting the manufacturer’s indication for donepezil (mild to moderate AD), the prevalence of use was 30% among newly admitted, and 19% among long-stay residents. About 3% of residents not meeting the manufacturer’s indication for donepezil were taking it. The proportion of people with AD still taking donepezil after six months was 44.8% among newly admitted, and 59.5% among long-stay residents. Donepezil use was associated with cognitive impairment, behavioral problems and the use of psychotropic drugs including antipsychotics and anti-depressants. In people without a diagnosis of AD, there seems to be an association between behavioral problems and use of donepezil. Conclusions: Donepezil is frequently used in the nursing home setting for the management of AD. Off-label use of donepezil is also relatively frequent. This may reflect an empirical perception of effectiveness on outcomes different from cognitive impairment, such as behavioral problems, although evidence is lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bernabei R, Gambassi G, Lapane K, et al. Characteristics of the SAGE database: a new resource for research on outcomes in long-term care. SAGE (Systematic Assessment of Geriatric drug use via Epidemiology) Study Group. J Gerontol 1999; 54: M25–33.

    Article  CAS  Google Scholar 

  2. Davis KL, Thal LJ, Gamzu ER, et al. A double blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253–9.

    Article  PubMed  CAS  Google Scholar 

  3. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293–303.

    PubMed  CAS  Google Scholar 

  4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021–31.

    Article  PubMed  CAS  Google Scholar 

  5. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998; 50: 136–45.

    Article  PubMed  CAS  Google Scholar 

  6. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of ri-vastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8.

    Article  PubMed  CAS  Google Scholar 

  7. Dubois B, McKeith I, Orgogozo JM, et al. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer’s disease: the MALT study. Int J Geriatr Psychiatry 1999; 14: 973–82.

    Article  PubMed  CAS  Google Scholar 

  8. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8.

    Article  PubMed  CAS  Google Scholar 

  9. Gifford DR, Lapane K, Gambassi G, et al. Tacrine use in nursing homes: implication for prescribing new cholinesterase inhibitors. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Neurology 1999; 52: 238–44.

    Article  PubMed  CAS  Google Scholar 

  10. Rogers SL. Perspectives in the management of Alzheimer’s disease: clinical profile of donepezil. Dement Geriatr Cogn Disord 1998; 9 (Suppl 3): 29–42.

    Article  PubMed  CAS  Google Scholar 

  11. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998; 32: 70–7.

    Article  PubMed  CAS  Google Scholar 

  12. Morris JC, Murphy K, Nonemaker S. Long term care facility Resident Assessment Instrument (RAI) user’s manual. Baltimore (MD): Health Care Financing Administration, 1995.

    Google Scholar 

  13. Morris JN, Fries BE, Mehr DR, et al. MDS cognitive performance scale. J Gerontol 1994; 49: M174–82.

    Article  PubMed  CAS  Google Scholar 

  14. Gambassi G, Landi F, Peng L, et al. Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Med Care 1998; 36: 167–79.

    Article  PubMed  CAS  Google Scholar 

  15. Phillips C, Morris JC. The potential use of administrative and clinical data to analyze otucomes for cognitively impaired. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 6): 162–7.

    PubMed  Google Scholar 

  16. Hartmeier SL, Sloane PD, Guess HA, Koch CG. The MDS cognition scale: a valid instrument for identifying and staging nursing home residents using the Minimum Data Set. J Am Geriatr Soc 1994; 42: 1173–80.

    Google Scholar 

  17. Katz S, Moskowitz RW, Jackson BA, Jeffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185: 94–9.

    Article  Google Scholar 

  18. Aronson MK, Cox D, Guastadisegni P, et al. Dementia and the nursing home: association with care needs. J Am Geriatr Soc 1992; 40: 27–33.

    PubMed  CAS  Google Scholar 

  19. Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional / behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry 2000; 61: 487–92.

    Article  PubMed  CAS  Google Scholar 

  20. Giacobini E. Is anti-cholinesterase therapy of Alzheimer’s disease delaying progression? Aging Clin Exp Res 2001; 13: 247–54.

    CAS  Google Scholar 

  21. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2000; 8: 134–40.

    PubMed  CAS  Google Scholar 

  22. Lanctôt KL, Herrmann N. Donepezil for behavioral disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000; 15: 338–45.

    Article  PubMed  Google Scholar 

  23. Mega MS, Masterman DM, O’Connor SM, et al. The spectrum of behavioral response to cholinesterase inhibitor therapy in Alzheimer’s disease. Arch Neurol 1999; 56: 1388–93.

    Article  PubMed  CAS  Google Scholar 

  24. Goodman LS, Gilman A. The pharmacological basis of therapeutics. New York: McMillan, 1993.

    Google Scholar 

  25. Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 1999; 21: 1230–40.

    Article  PubMed  CAS  Google Scholar 

  26. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999; 52: 1138–45.

    Article  PubMed  CAS  Google Scholar 

  27. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 2000; 15: 280–1.

    Article  PubMed  CAS  Google Scholar 

  28. Belloni-Sonzogni A, Tissot A, Tettamanti M, et al. Mortality of demented patients in a geriatric institution. Arch Gerontol Geriatr 1989; 9: 193–7.

    Article  PubMed  CAS  Google Scholar 

  29. Landi F, Gambassi G, Lapane K, et al. Impact of the type and severity of dementia on hospitalization and survival of the elderly. Dement Geriatr Cogn Disord 1999; 10: 121–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro di Medicina dell’Invecchiamento (CE.M.I.), Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Roma, Italy

    Claudio Pedone MD, PhD & Roberto Bernabei

  2. Center for Gerontology and Health Care Research, Brown University, Providence RI, USA

    Kate L. Lapane & Vince Mor

  3. Department of Community Health, Brown University School of Medicine, Providence RI, USA

    Kate L. Lapane & Vince Mor

Authors
  1. Claudio Pedone MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate L. Lapane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vince Mor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Bernabei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudio Pedone MD, PhD.

Additional information

An abstract of this paper was presented at the Annual Meeting of the American Geriatrics Society, Chicago IL, May 2001

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedone, C., Lapane, K.L., Mor, V. et al. Donepezil use in US nursing homes. Aging Clin Exp Res 16, 60–67 (2004). https://doi.org/10.1007/BF03324534

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324534

Keywords

Search

Navigation